Application for Ibrutinib to preparation of drugs for resisting severe hepatitis
The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | YE BINGJUE LIU YANNING ZHENG MIN ZHOU CHENG LOU GUOHUA |
| description | The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-mediated mouse severe hepatitis model is utilized to verify the inhibitory effect of Ibrutinib on liver functions and liver pathology; and endotoxin (LPS) is utilized to verify the anti-inflammatory effect of Ibrutinib at a cellular level. In-vitro and in-vivo experimental results prove that Ibrutinib has strong inhibitory effect on the occurence and development of the severe hepatitis. Meanwhile, Ibrutinib has a clear target and indications, is applicable to clinical practice, and can be used as a drug for the treatment of severe hepatitis. The invention provides the novel medical application of Ibrutinib, and Ibrutinib provides a novel means for treatment of severe hepatitis.
本发明的目的是提供依鲁替尼(Ibrutinib)在制备抗重症肝炎药物中的应 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN108478580A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN108478580A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN108478580A3</originalsourceid><addsrcrecordid>eNqNyjEKwkAQQNFtLES9w3gAIaLitiEo2oiFfdjE2WQg7A4zE89vUA9g9Yv_5u5eMg_UBqOcIGaBayOjUaIGLAMLcpDvzBGeMnb6UYJKOrEOFF8oCP0EjYx06WYxDIqrXxdufT49qssGOdeoHFpMaHV12xZ-f_QHX5S7f8wb0o034g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application for Ibrutinib to preparation of drugs for resisting severe hepatitis</title><source>esp@cenet</source><creator>YE BINGJUE ; LIU YANNING ; ZHENG MIN ; ZHOU CHENG ; LOU GUOHUA</creator><creatorcontrib>YE BINGJUE ; LIU YANNING ; ZHENG MIN ; ZHOU CHENG ; LOU GUOHUA</creatorcontrib><description>The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-mediated mouse severe hepatitis model is utilized to verify the inhibitory effect of Ibrutinib on liver functions and liver pathology; and endotoxin (LPS) is utilized to verify the anti-inflammatory effect of Ibrutinib at a cellular level. In-vitro and in-vivo experimental results prove that Ibrutinib has strong inhibitory effect on the occurence and development of the severe hepatitis. Meanwhile, Ibrutinib has a clear target and indications, is applicable to clinical practice, and can be used as a drug for the treatment of severe hepatitis. The invention provides the novel medical application of Ibrutinib, and Ibrutinib provides a novel means for treatment of severe hepatitis.
本发明的目的是提供依鲁替尼(Ibrutinib)在制备抗重症肝炎药物中的应</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180904&DB=EPODOC&CC=CN&NR=108478580A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180904&DB=EPODOC&CC=CN&NR=108478580A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>YE BINGJUE</creatorcontrib><creatorcontrib>LIU YANNING</creatorcontrib><creatorcontrib>ZHENG MIN</creatorcontrib><creatorcontrib>ZHOU CHENG</creatorcontrib><creatorcontrib>LOU GUOHUA</creatorcontrib><title>Application for Ibrutinib to preparation of drugs for resisting severe hepatitis</title><description>The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-mediated mouse severe hepatitis model is utilized to verify the inhibitory effect of Ibrutinib on liver functions and liver pathology; and endotoxin (LPS) is utilized to verify the anti-inflammatory effect of Ibrutinib at a cellular level. In-vitro and in-vivo experimental results prove that Ibrutinib has strong inhibitory effect on the occurence and development of the severe hepatitis. Meanwhile, Ibrutinib has a clear target and indications, is applicable to clinical practice, and can be used as a drug for the treatment of severe hepatitis. The invention provides the novel medical application of Ibrutinib, and Ibrutinib provides a novel means for treatment of severe hepatitis.
本发明的目的是提供依鲁替尼(Ibrutinib)在制备抗重症肝炎药物中的应</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyjEKwkAQQNFtLES9w3gAIaLitiEo2oiFfdjE2WQg7A4zE89vUA9g9Yv_5u5eMg_UBqOcIGaBayOjUaIGLAMLcpDvzBGeMnb6UYJKOrEOFF8oCP0EjYx06WYxDIqrXxdufT49qssGOdeoHFpMaHV12xZ-f_QHX5S7f8wb0o034g</recordid><startdate>20180904</startdate><enddate>20180904</enddate><creator>YE BINGJUE</creator><creator>LIU YANNING</creator><creator>ZHENG MIN</creator><creator>ZHOU CHENG</creator><creator>LOU GUOHUA</creator><scope>EVB</scope></search><sort><creationdate>20180904</creationdate><title>Application for Ibrutinib to preparation of drugs for resisting severe hepatitis</title><author>YE BINGJUE ; LIU YANNING ; ZHENG MIN ; ZHOU CHENG ; LOU GUOHUA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN108478580A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>YE BINGJUE</creatorcontrib><creatorcontrib>LIU YANNING</creatorcontrib><creatorcontrib>ZHENG MIN</creatorcontrib><creatorcontrib>ZHOU CHENG</creatorcontrib><creatorcontrib>LOU GUOHUA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>YE BINGJUE</au><au>LIU YANNING</au><au>ZHENG MIN</au><au>ZHOU CHENG</au><au>LOU GUOHUA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application for Ibrutinib to preparation of drugs for resisting severe hepatitis</title><date>2018-09-04</date><risdate>2018</risdate><abstract>The objective of the invention is to provide application for Ibrutinib to preparation of drugs for resisting severe hepatitis. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. According to the invention, a ConA-mediated mouse severe hepatitis model is utilized to verify the inhibitory effect of Ibrutinib on liver functions and liver pathology; and endotoxin (LPS) is utilized to verify the anti-inflammatory effect of Ibrutinib at a cellular level. In-vitro and in-vivo experimental results prove that Ibrutinib has strong inhibitory effect on the occurence and development of the severe hepatitis. Meanwhile, Ibrutinib has a clear target and indications, is applicable to clinical practice, and can be used as a drug for the treatment of severe hepatitis. The invention provides the novel medical application of Ibrutinib, and Ibrutinib provides a novel means for treatment of severe hepatitis.
本发明的目的是提供依鲁替尼(Ibrutinib)在制备抗重症肝炎药物中的应</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN108478580A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Application for Ibrutinib to preparation of drugs for resisting severe hepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T23%3A56%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=YE%20BINGJUE&rft.date=2018-09-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN108478580A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |